{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:57:28Z","timestamp":1757311048915},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1245\/s10434-022-12063-5","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:04:06Z","timestamp":1657703046000},"page":"7123-7132","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ten-Year Survivorship in Patients with Metastatic Gastrointestinal Stromal Tumors"],"prefix":"10.1245","volume":"29","author":[{"given":"Thomas L.","family":"Sutton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin G.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Corless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett C.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Skye C.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"issue":"10","key":"12063_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0046-8177(99)90040-0","volume":"30","author":"M Miettinen","year":"1999","unstructured":"Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathol. 1999;30(10):1213\u201320.","journal-title":"Human Pathol."},{"issue":"1","key":"12063_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1146\/annurev.pathmechdis.3.121806.151538","volume":"3","author":"CL Corless","year":"2008","unstructured":"Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Ann Rev Pathol. 2008;3(1):557\u201386.","journal-title":"Ann Rev Pathol."},{"issue":"12","key":"12063_CR3","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s12094-019-02094-y","volume":"21","author":"DY Yang","year":"2019","unstructured":"Yang DY, Wang X, Yuan WJ, Chen ZH. Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis. Clin and Trans Oncol. 2019;21(12):1654\u201362.","journal-title":"Clin and Trans Oncol."},{"key":"12063_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/2156-7514.99177","volume":"2","author":"S Patnaik","year":"2012","unstructured":"Patnaik S, Jyotsnarani Y, Rammurti S. Radiological features of metastatic gastrointestinal stromal tumors. J Clin Imag Sci. 2012;2:43.","journal-title":"J. Clin Imag Sci."},{"issue":"3","key":"12063_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","volume":"13","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Vehtari A, Riihim\u00e4ki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265\u201374.","journal-title":"Lancet Oncol."},{"issue":"1","key":"12063_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1245\/s10434-006-9177-7","volume":"14","author":"JS Gold","year":"2007","unstructured":"Gold JS, van der Zwan SM, G\u00f6nen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol. 2007;14(1):134\u201342.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"12063_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/bjs.10809","volume":"105","author":"WTA van der Graaf","year":"2018","unstructured":"van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. The British J Surg. 2018;105(8):1020\u20137.","journal-title":"The British J Surg."},{"issue":"15 Suppl","key":"12063_CR8","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.1200\/jco.2014.32.15_suppl.10508","volume":"32","author":"GD Demetri","year":"2014","unstructured":"Demetri GD, Rankin CJ, Benjamin RS, et al. Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. J Clin Oncol. 2014;32(15 Suppl):10508.","journal-title":"J Clin Oncol."},{"issue":"12","key":"12063_CR9","doi-asserted-by":"publisher","first-page":"e184060","DOI":"10.1001\/jamaoncol.2018.4060","volume":"4","author":"CP Raut","year":"2018","unstructured":"Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4(12):e184060.","journal-title":"JAMA Oncol."},{"issue":"10","key":"12063_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/0284186X.2017.1330555","volume":"56","author":"I Hompland","year":"2017","unstructured":"Hompland I, Bruland \u00d8S, H\u00f8lmebakk T, et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta oncologica. 2017;56(10):1317\u201323.","journal-title":"Acta oncologica."},{"issue":"3","key":"12063_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/cam4.1994","volume":"8","author":"JH Kim","year":"2019","unstructured":"Kim JH, Ryu MH, Yoo C, et al. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Cancer Med. 2019;8(3):1034\u201343.","journal-title":"Cancer Med."},{"issue":"7","key":"12063_CR12","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","volume":"3","author":"MC Heinrich","year":"2017","unstructured":"Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 swog intergroup trial S0033. JAMA Oncol. 2017;3(7):944\u201352.","journal-title":"JAMA Oncol."},{"key":"12063_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13569-019-0114-5","volume":"9","author":"JW Call","year":"2019","unstructured":"Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from life raft group registry. Clin Sarcoma Res. 2019;9:4.","journal-title":"Clin Sarcoma Res."},{"issue":"6","key":"12063_CR14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.hpb.2021.11.011","volume":"24","author":"TL Sutton","year":"2022","unstructured":"Sutton TL, Walker BS, Billingsley KG, et al. Hepatic metastases in gastrointestinal stromal tumors: oncologic outcomes with curative-intent hepatectomy, resection of treatment-resistant disease, and tyrosine kinase inhibitor therapy alone. HPB (Oxford). 2022;24(6):986\u201393.","journal-title":"HPB (Oxford)."},{"issue":"1","key":"12063_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/jso.23451","volume":"109","author":"ZM Bamboat","year":"2014","unstructured":"Bamboat ZM, DeMatteo RP. Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol. 2014;109(1):23\u20137.","journal-title":"J Surg Oncol."},{"issue":"12","key":"12063_CR16","doi-asserted-by":"publisher","first-page":"7912","DOI":"10.1245\/s10434-021-10062-6","volume":"28","author":"TL Sutton","year":"2021","unstructured":"Sutton TL, Walker BS, Billingsley KG, et al. Disease-free interval is associated with oncologic outcomes in patients with recurrent gastrointestinal stromal tumor. Annals Surg Oncol. 2021;28(12):7912\u201320.","journal-title":"Annals Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12063-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:21:46Z","timestamp":1663773706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12063-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["12063"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12063-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Heinrich receives consulting fees from Novartis, Deciphera Pharmaceuticals, Blueprint Medicines, and Theseus Pharmaceuticals, and holds multiple patents on the diagnosis and\/or treatment of GIST. One patent on the treatment of GIST has been licensed by OHSU to Novartis. Thomas L. Sutton, Brett S. Walker, Kevin G. Billingsley, Christopher L. Corless, Brett C. Sheppard, and Skye C. Mayo have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}